Search

Displaying results 2281 - 2290 of 10000 in total
  1. Drug

    Nifurtimox

    go.drugbank.com/drugs/DB11820
    ApprovedInvestigational

    On August 6 2020, accelerated FDA approval was granted for its use in pediatric patients in response to promising results from phase III clinical trials.

  2. Drug

    Iopodic acid

    go.drugbank.com/drugs/DB09333
    ApprovedWithdrawn

    This drug was approved on March 15, 1962 but it is nowadays discontinued from the FDA and Health Canada. … On September 22, 1981, ipodate was submitted again by the company Schering AG but it is currently under an inactive status.[L1082]

  3. Drug

    Vorasidenib

    go.drugbank.com/drugs/DB17097
    ApprovedInvestigational

    [A264209] It works by suppressing the levels of D-2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH1 and IDH2 isoforms. … [L51139] Vorasidenib displayed improved brain penetration and higher drug exposure compared to other IDH inhibitors such as [ivosidenib] and [enasidenib].

  4. Drug

    NOX-100

    go.drugbank.com/drugs/DB05799
    Investigational

    NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock. … NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body.

  5. Drug

    Artenimol

    go.drugbank.com/drugs/DB11638
    ApprovedInvestigational

    Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated Plasmodium falciparum infections [FDA Label]. It was first authorized for market by the European Medicines Agency in October 2011 in com...

    Mixtures: EURARTESIM 320 MG/40 MG FILM COATED TABLETS
  6. Drug

    Piperaquine

    go.drugbank.com/drugs/DB13941
    ApprovedInvestigational

    It has come back into use in combination with the artemisinin derivative [DB11638] as part of the combination product Eurartesim [FDA Label].

    Mixtures: EURARTESIM 320 MG/40 MG FILM COATED TABLETS
  7. Drug

    Inebilizumab

    go.drugbank.com/drugs/DB12530
    ApprovedInvestigational

    [A214280, A214289, A214292, A214295, A214298, A214301] Inebilizumab was granted initially FDA approval on June 11, 2020, for the treatment of anti-aquaporin 4 positive NMOSD patients. … Compared to the anti-CD20 antibody [rituximab], which is also used to treat NMOSD, inebilizumab has broader specificity.

  8. Drug

    Zomepirac

    go.drugbank.com/drugs/DB04828
    ApprovedWithdrawn

    The manufacturer voluntarily removed Zomax tablets from the Canadian, US, and UK markets in March 1983.

  9. Target

    Cytochrome b-c1 complex subunit 1, mitochondrial

    go.drugbank.com/bio_entities/BE0001005
    TargetHumans

    The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase … Component of the ubiquinol-cytochrome c oxidoreductase, a multisubunit transmembrane complex that is part of the mitochondrial electron transport chain which drives oxidative phosphorylation.

    Polypeptides: Cytochrome b-c1 complex subunit 1, mitochondrialSynonyms: Ubiquinol-cytochrome-c reductase complex core protein 1, Core protein I
  10. Target

    Holliday junction branch migration complex subunit RuvB

    go.drugbank.com/bio_entities/BE0002792
    TargetThermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)

    The RuvA-RuvB-RuvC complex processes Holliday junction (HJ) DNA during genetic recombination and DNA repair, while the RuvA-RuvB complex plays an important role in the rescue of blocked DNA replication … The RuvB hexamer acts as an ATP-dependent pump, pulling dsDNA into and through the RuvAB complex.

    Polypeptides: Holliday junction branch migration complex subunit RuvB